Targeted News Service

GSK: Blenrep (Belantamab Mafodotin) Combinations in Relapsed/Refractory Multiple Myeloma Accepted for Regulatory Review in Japan
September 19, 2024

LONDON, England, Sept. 19 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Sept. 17, 2024:

* * *

* Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials

* If approved, Blenrep plus BorDex or PomDex could redefine relapsed/refractory multiple myeloma treatment landscape

* More than 7,200 new cases of multiple myeloma are diagnosed in Japan each year/1

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form